These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15666999)

  • 1. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
    Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
    Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs from the sea.
    D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
    J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
    Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
    Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
    David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
    Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
    Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
    Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique features of the mode of action of ET-743.
    D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
    Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
    Aune GJ; Furuta T; Pommier Y
    Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
    Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
    Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
    Tognon G; Frapolli R; Zaffaroni M; Erba E; Zucchetti M; Faircloth GT; D'Incalci M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
    van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
    Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
    Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
    Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
    Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
    Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.
    Marco E; Gago F
    Mol Pharmacol; 2005 Dec; 68(6):1559-67. PubMed ID: 16150929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
    Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
    Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
    Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
    [No Abstract]   [Full Text] [Related]  

  • 18. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
    Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C; Francesch A
    Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
    Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
    Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.